Nanocarrier-based Systems for Targeted and Site Specific Therapeutic Delivery

Overview

Journal Adv Drug Deliv Rev

Specialty Pharmacology

Date 2019 Aug 11

PMID 31400350

Citations 91

Authors

Joydeb Majumder

Oleh Taratula

Tamara Minko

Affiliations

Soon will be listed here.

Abstract

Systemic drug delivery methods such as oral or parenteral administration of free drugs possess relatively low treatment efficiency and marked adverse side effects. The use of nanoparticles for drug delivery in most cases substantially enhances drug efficacy, improves pharmacokinetics and drug release and limits their side effects. However, further enhancement in drug efficacy and significant limitation of adverse side effects can be achieved by specific targeting of nanocarrier-based delivery systems especially in combination with local administration. The present review describes major advantages and limitations of organic and inorganic nanocarriers or living cell-based drug and nucleic acid delivery systems. Among these, different nanoparticles, supramolecular gels, therapeutic cells as living drug carriers etc. have emerged as a new frontier in modern medicine.

Citing Articles

Investigation on the Interaction of Dendritic Core Multi-Shell Nanoparticles with Human Red Blood Cells.

Krauss J, Georgieva R, Karabaliev M, Hackmann M, Rerkshanandana P, Chaiwaree S Nanomaterials (Basel). 2025; 15(3).

PMID: 39940163 PMC: 11820349. DOI: 10.3390/nano15030187.

A systematic review of nanocarriers used in medicine and beyond - definition and categorization framework.

Gressler S, Hipfinger C, Part F, Pavlicek A, Zafiu C, Giese B J Nanobiotechnology. 2025; 23(1):90.

PMID: 39920688 PMC: 11804063. DOI: 10.1186/s12951-025-03113-7.

Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy.

Shao X, Zhao X, Wang B, Fan J, Wang J, An H Theranostics. 2025; 15(5):1689-1714.

PMID: 39897552 PMC: 11780529. DOI: 10.7150/thno.103636.

CT-sensitized nanoprobe for effective early diagnosis and treatment of pulmonary fibrosis.

Hou J, Ji Q, Tang T, Xue Y, Gao L, Dai L J Nanobiotechnology. 2025; 23(1):60.

PMID: 39881299 PMC: 11776250. DOI: 10.1186/s12951-025-03128-0.

Nanomedicine in HNSCC therapy-a challenge to conventional therapy.

Li C, Fang Y, Xu S, Zhao J, Dong D, Li S Front Pharmacol. 2024; 15:1434994.

PMID: 39469621 PMC: 11513379. DOI: 10.3389/fphar.2024.1434994.

References

Frigerio B, Bizzoni C, Jansen G, Leamon C, Peters G, Low P . Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases. J Exp Clin Cancer Res. 2019; 38(1):125. PMC: 6417013. DOI: 10.1186/s13046-019-1123-1. View

Lungwitz U, Breunig M, Blunk T, Gopferich A . Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm. 2005; 60(2):247-66. DOI: 10.1016/j.ejpb.2004.11.011. View

Rodriguez M, Pytlik R, Kozak T, Chhanabhai M, Gascoyne R, Lu B . Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer. 2009; 115(15):3475-82. DOI: 10.1002/cncr.24359. View

Waite C, Roth C . Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit Rev Biomed Eng. 2012; 40(1):21-41. PMC: 3639314. DOI: 10.1615/critrevbiomedeng.v40.i1.20. View

Usonis V, Bakasenas V, Valentelis R, Katiliene G, Vidzeniene D, Herzog C . Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). Vaccine. 2003; 21(31):4588-92. DOI: 10.1016/s0264-410x(03)00509-7. View

Akao Y, Iio A, Itoh T, Noguchi S, Itoh Y, Ohtsuki Y . Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol Ther. 2010; 19(2):395-9. PMC: 3034851. DOI: 10.1038/mt.2010.254. View

Piepenbrock M, Lloyd G, Clarke N, Steed J . Metal- and anion-binding supramolecular gels. Chem Rev. 2009; 110(4):1960-2004. DOI: 10.1021/cr9003067. View

Luo Y, Zhai X, Ma C, Sun P, Fu Z, Liu W . An inhalable β₂-adrenoceptor ligand-directed guanidinylated chitosan carrier for targeted delivery of siRNA to lung. J Control Release. 2012; 162(1):28-36. DOI: 10.1016/j.jconrel.2012.06.005. View

Beloqui A, Solinis M, Rodriguez-Gascon A, Almeida A, Preat V . Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine. 2015; 12(1):143-61. DOI: 10.1016/j.nano.2015.09.004. View

10.

Acharya S, Sahoo S . PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2010; 63(3):170-83. DOI: 10.1016/j.addr.2010.10.008. View

11.

Moody T, Nuche-Berenguer B, Nakamura T, Jensen R . EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer. Curr Drug Targets. 2015; 17(5):520-8. DOI: 10.2174/1389450116666150107153609. View

12.

Panyam J, Labhasetwar V . Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003; 55(3):329-47. DOI: 10.1016/s0169-409x(02)00228-4. View

13.

Stuckey D, Shah K . Stem cell-based therapies for cancer treatment: separating hope from hype. Nat Rev Cancer. 2014; 14(10):683-91. PMC: 4234304. DOI: 10.1038/nrc3798. View

14.

Hamidi M, Zarrin A, Foroozesh M, Mohammadi-Samani S . Applications of carrier erythrocytes in delivery of biopharmaceuticals. J Control Release. 2007; 118(2):145-60. DOI: 10.1016/j.jconrel.2006.06.032. View

15.

Han F, Yin R, Che X, Yuan J, Cui Y, Yin H . Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design, characterization and in vivo evaluation. Int J Pharm. 2012; 439(1-2):349-57. DOI: 10.1016/j.ijpharm.2012.08.040. View

16.

Xu C, Tian H, Wang P, Wang Y, Chen X . The suppression of metastatic lung cancer by pulmonary administration of polymer nanoparticles for co-delivery of doxorubicin and Survivin siRNA. Biomater Sci. 2016; 4(11):1646-1654. DOI: 10.1039/c6bm00601a. View

17.

Wang Q, Yang Z, Zhang X, Xiao X, Chang C, Xu B . A supramolecular-hydrogel-encapsulated hemin as an artificial enzyme to mimic peroxidase. Angew Chem Int Ed Engl. 2007; 46(23):4285-9. DOI: 10.1002/anie.200700404. View

18.

Moody T, Nuche-Berenguer B, Jensen R . Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer. Curr Opin Endocrinol Diabetes Obes. 2015; 23(1):38-47. PMC: 4844466. DOI: 10.1097/MED.0000000000000218. View

19.

Dani R, Schumann C, Taratula O, Taratula O . Temperature-tunable iron oxide nanoparticles for remote-controlled drug release. AAPS PharmSciTech. 2014; 15(4):963-72. PMC: 4113623. DOI: 10.1208/s12249-014-0131-x. View

20.

Gaba B, Fazil M, Ali A, Baboota S, Sahni J, Ali J . Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Drug Deliv. 2014; 22(6):691-700. DOI: 10.3109/10717544.2014.898110. View